This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
THE NATIONAL Heart, Lung, and Blood Institute (NHLBI), Bethesda, Md, has taken the unusual step of curtailing one of its major clinical trials—the β-Blocker Heart Attack Trial (BHAT)—on the advice of its Policy and Data Monitoring Board. The step was taken after data indicated that the group of patients receiving propranolol hydrochloride experienced a 26% lower mortality from all causes than did a control group.
The BHAT was a randomized, double-blind, multicenter clinical trial of propranolol vs placebo in patients enrolled five to 21 days after the onset of an acute myocardial infarction. The primary objective was to determine if long-term administration of propranolol in this population would result in a significant reduction in total mortality over the follow-up period. Thirty-one clinical centers, a coordinating center, a resting ECG reading center, a 24-hour ambulatory ECG reading center, a central laboratory, a drug distribution center, and an NHLBI program office were
The β-Blocker Heart Attack Trial. JAMA. 1981;246(18):2073–2074. doi:10.1001/jama.1981.03320180063037
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: